O	0	13	Effectiveness
O	14	16	of
B-intervention	17	27	biosimilar
I-intervention	28	38	filgrastim
O	39	41	vs
O	41	42	.
B-control	43	51	original
I-control	52	63	granulocyte
I-control	64	70	colony
I-control	70	71	-
I-control	71	82	stimulating
I-control	83	90	factors
O	91	93	in
O	94	101	febrile
O	102	113	neutropenia
O	114	124	prevention
O	125	127	in
O	128	134	breast
O	135	141	cancer
O	142	150	patients
O	150	151	.

O	152	155	The
O	156	163	purpose
O	164	166	of
O	167	171	this
O	172	177	study
O	178	180	is
O	181	183	to
O	184	192	describe
O	193	196	the
O	197	210	effectiveness
O	211	213	of
O	214	224	biosimilar
O	225	235	filgrastim
O	236	239	and
O	240	248	original
O	249	260	granulocyte
O	261	267	colony
O	267	268	-
O	268	279	stimulating
O	280	287	factors
O	288	289	(
O	289	290	G
O	290	291	-
O	291	295	CSFs
O	295	296	)
O	296	297	,
O	298	309	lenograstim
O	310	313	and
O	314	327	pegfilgrastim
O	327	328	,
O	329	331	in
O	332	339	febrile
O	340	351	neutropenia
O	352	353	(
O	353	355	FN
O	355	356	)
O	357	367	prevention
O	368	370	in
B-eligibility	371	377	breast
I-eligibility	378	384	cancer
I-eligibility	385	393	patients
I-eligibility	394	403	receiving
I-eligibility	404	413	docetaxel
I-eligibility	413	414	/
I-eligibility	414	425	doxorubicin
I-eligibility	425	426	/
I-eligibility	426	442	cyclophosphamide
I-eligibility	443	444	(
I-eligibility	444	447	TAC
I-eligibility	447	448	)
I-eligibility	449	451	as
I-eligibility	452	460	adjuvant
I-eligibility	460	461	/
I-eligibility	461	472	neoadjuvant
I-eligibility	473	482	treatment
O	483	486	and
O	487	489	to
O	490	497	analyze
O	498	503	their
O	504	513	treatment
O	514	522	patterns
O	522	523	.

O	524	525	A
O	526	546	pharmacoepidemiology
O	547	553	cohort
O	554	559	study
O	560	563	was
O	564	573	developed
O	574	576	in
O	577	578	a
O	579	589	university
O	590	598	hospital
O	599	600	(
O	600	604	with
O	605	607	23
O	608	618	healthcare
O	619	626	centers
O	626	627	)
O	628	632	with
O	633	646	retrospective
O	647	651	data
O	652	662	collection
O	663	664	(
O	664	668	2012
O	668	669	-
O	669	673	2014
O	673	674	)
O	674	675	.

O	676	689	Effectiveness
O	690	692	of
O	693	694	G
O	694	695	-
O	695	699	CSFs
O	700	703	was
O	704	712	assessed
O	713	715	by
O	716	719	the
B-outcome-Measure	720	722	FN
I-outcome-Measure	723	732	incidence
O	732	733	.

O	734	739	Other
O	740	750	parameters
O	751	759	analyzed
O	760	764	were
O	765	767	as
O	768	775	follows
O	775	776	:
O	777	785	moderate
O	786	789	and
O	790	796	severe
O	797	808	neutropenia
O	809	818	incidence
O	818	819	,
O	820	831	neutropenia
O	831	832	-
O	832	839	related
O	840	856	hospitalizations
O	856	857	,
O	858	864	dosage
O	864	865	,
O	866	869	and
O	870	878	duration
O	878	879	.

O	880	884	Data
O	885	888	was
O	889	897	analyzed
O	898	903	using
O	904	908	each
O	909	914	cycle
O	915	917	as
O	918	919	a
O	920	924	unit
O	925	927	of
O	928	936	analysis
O	936	937	.

O	938	940	We
O	941	951	identified
B-total-participants	952	954	98
O	955	963	patients
O	964	976	representing
O	977	980	518
O	981	993	chemotherapy
O	994	1000	cycles
O	1000	1001	,
O	1002	1005	215
O	1006	1010	with
O	1011	1019	original
O	1020	1021	G
O	1021	1022	-
O	1022	1026	CSFs
O	1027	1028	(
O	1028	1030	35
O	1031	1042	lenograstim
O	1043	1046	and
O	1047	1050	180
O	1051	1064	pegfilgrastim
O	1064	1065	)
O	1066	1069	and
O	1070	1073	303
O	1074	1078	with
O	1079	1089	biosimilar
O	1090	1100	filgrastim
O	1100	1101	.

O	1102	1105	The
B-outcome	1106	1108	FN
I-outcome	1109	1118	incidence
O	1119	1122	was
O	1123	1130	similar
O	1131	1133	in
O	1134	1138	both
O	1139	1145	groups
O	1146	1147	(
B-cv-bin-percent	1147	1148	3
I-cv-bin-percent	1148	1149	.
I-cv-bin-percent	1149	1150	7
I-cv-bin-percent	1150	1151	%
O	1152	1160	original
O	1161	1163	vs
O	1163	1164	.
B-iv-bin-percent	1165	1166	3
I-iv-bin-percent	1166	1167	.
I-iv-bin-percent	1167	1168	3
I-iv-bin-percent	1168	1169	%
O	1170	1180	biosimilar
O	1180	1181	;
O	1182	1183	p
O	1184	1185	=
O	1186	1187	0
O	1187	1188	.
O	1188	1190	79
O	1190	1191	)
O	1191	1192	.

O	1193	1195	No
O	1196	1209	statistically
O	1210	1221	significant
O	1222	1233	differences
O	1234	1238	were
O	1239	1244	found
O	1245	1247	in
B-outcome	1248	1256	moderate
I-outcome	1257	1260	and
I-outcome	1261	1267	severe
I-outcome	1268	1279	neutropenia
I-outcome	1280	1289	incidence
O	1290	1291	(
B-cv-bin-percent	1291	1292	4
I-cv-bin-percent	1292	1293	.
I-cv-bin-percent	1293	1294	7
O	1295	1297	vs
O	1297	1298	.
B-iv-bin-percent	1299	1300	6
I-iv-bin-percent	1300	1301	.
I-iv-bin-percent	1301	1302	3
I-iv-bin-percent	1302	1303	%
O	1303	1304	;
O	1305	1306	p
O	1307	1308	=
O	1309	1310	0
O	1310	1311	.
O	1311	1313	43
O	1313	1314	)
O	1315	1317	or
B-outcome	1318	1329	neutropenia
I-outcome	1329	1330	-
I-outcome	1330	1337	related
I-outcome	1338	1354	hospitalizations
O	1355	1356	(
B-cv-bin-percent	1356	1357	3
I-cv-bin-percent	1357	1358	.
I-cv-bin-percent	1358	1359	3
O	1360	1362	vs
O	1362	1363	.
B-iv-bin-percent	1364	1365	3
I-iv-bin-percent	1365	1366	.
I-iv-bin-percent	1366	1367	6
I-iv-bin-percent	1367	1368	%
O	1368	1369	;
O	1370	1371	p
O	1372	1373	=
O	1374	1375	0
O	1375	1376	.
O	1376	1378	19
O	1378	1379	)
O	1379	1380	.

O	1381	1385	When
O	1386	1389	the
O	1390	1395	three
O	1396	1401	drugs
O	1402	1406	were
O	1407	1416	evaluated
O	1417	1427	separately
O	1427	1428	,
O	1429	1430	a
O	1431	1437	higher
B-outcome	1438	1440	FN
I-outcome	1441	1450	incidence
O	1451	1454	was
O	1455	1463	observed
O	1464	1468	with
O	1469	1480	lenograstim
O	1481	1485	than
O	1486	1490	with
O	1491	1503	pegfilgratim
O	1504	1506	or
O	1507	1517	biosimilar
O	1518	1519	(
O	1519	1520	p
O	1521	1522	=
O	1523	1524	0
O	1524	1525	.
O	1525	1528	024
O	1528	1529	)
O	1529	1530	.

O	1531	1534	The
B-outcome	1535	1541	dosage
I-outcome	1542	1545	and
I-outcome	1546	1554	duration
O	1555	1557	of
O	1558	1568	biosimilar
O	1569	1573	were
O	1574	1579	lower
O	1580	1584	than
O	1585	1596	lenograstim
O	1597	1598	(
B-iv-cont-mean	1598	1599	4
I-iv-cont-mean	1599	1600	.
I-iv-cont-mean	1600	1601	9
O	1602	1604	vs
O	1604	1605	.
B-cv-cont-mean	1606	1607	5
I-cv-cont-mean	1607	1608	.
I-cv-cont-mean	1608	1609	7
I-cv-cont-mean	1610	1611	Î¼
I-cv-cont-mean	1611	1612	g
I-cv-cont-mean	1612	1613	/
I-cv-cont-mean	1613	1615	kg
I-cv-cont-mean	1615	1616	/
I-cv-cont-mean	1616	1619	day
O	1619	1620	;
B-iv-cont-mean	1621	1622	5
O	1623	1625	vs
O	1625	1626	.
B-cv-cont-mean	1627	1628	7
I-cv-cont-mean	1629	1633	days
O	1633	1634	;
O	1635	1636	p
O	1637	1638	<
O	1639	1640	0
O	1640	1641	.
O	1641	1644	001
O	1644	1645	)
O	1645	1646	.

O	1647	1649	An
O	1650	1661	abbreviated
O	1662	1663	5
O	1663	1664	-
O	1664	1667	day
O	1668	1674	course
O	1675	1677	of
O	1678	1688	biosimilar
O	1689	1699	filgrastim
O	1700	1708	provided
O	1709	1716	optimal
O	1717	1724	primary
O	1725	1736	prophylaxis
O	1737	1744	against
O	1745	1747	FN
O	1748	1752	post
O	1752	1753	-
O	1753	1765	chemotherapy
O	1766	1769	TAC
O	1770	1772	in
O	1773	1781	patients
O	1782	1786	with
O	1787	1793	breast
O	1794	1800	cancer
O	1800	1801	.

O	1802	1805	The
O	1806	1814	clinical
O	1815	1824	relevance
O	1825	1827	of
O	1828	1831	the
O	1832	1839	highest
O	1840	1842	FN
O	1843	1852	incidence
O	1853	1855	in
O	1856	1859	the
O	1860	1871	lenograstim
O	1872	1878	cohort
O	1879	1884	needs
O	1885	1892	further
O	1893	1902	attention
O	1902	1903	.
